Welcome to Paid Research Studies




  • Condition:   Mantle Cell Lymphoma (MCL)
    Interventions:   Drug: Acalabrutinib in combination with BR;   Drug: Acalabrutinib in combination with VR
    Sponsor:   Acerta Pharma BV
    Recruiting

  • Conditions:   Kawasaki Disease;   Atypical Kawasaki Disease
    Intervention:  
    Sponsors:   Imperial College London;   Guy's and St Thomas' NHS Foundation Trust;   University Hospitals Bristol NHS Foundation Trust;   Great Ormond Street Hospital for Children NHS Foundation Trust;   UK Kawasaki Support Group;   Imperial College Healthcare NHS Trust;   University Hospitals of North Midlands NHS Trust;   Burton Hospitals NHS Foundation Trust;   York Teaching Hospitals NHS Foundation Trust;   The Shrewsbury and Telford Hospital NHS Trust;   East Suffolk and North Essex NHS Foundation Trust;   New Cross Hospital;   Darlington Memorial Hospital;   Torbay Hospital;   Peterborough City Hospital;   University Hospitals Coventry and Warwickshire NHS Trust;   University Hospital of North Tees;   Cambridge University Hospitals NHS Foundation Trust;   Royal Cornwall Hospitals Trust;   Birmingham Children’s Hospital;   Birmingham Heartlands Hospital;   Wye Valley NHS Trust;   South Tees Hospitals NHS Foundation Trust;   Leeds General Infirmary;   Bradford Royal Infirmary;   University Hospitals of Morecambe Bay NHS Trust;   Calderdale and Huddersfield NHS Foundation Trust;   St. Richard's Hospital;   Pinderfields General Hospital;   Worthing Hospital;   Airedale General Hospital;   Sheffield Children's NHS Foundation Trust;   Northwick Park Hospital;   West Middlesex Hospital;   Royal Albert Edward Infirmary;   Macclesfield District General Hospital;   Royal Oldham Hospital;   Stepping Hill Hospital;   North Manchester General Hospital;   Royal Bolton Hospital NHS Foundation Trust;   Kingston Hospital NHS Trust;   Tameside Hospital NHS Foundation Trust;   East Surrey Hospital;   St. George's Hospital, London;   Royal Alexandra Children's Hospital
    Recruiting

  • Condition:   Mantle Cell Lymphoma (MCL)
    Interventions:   Drug: Copanlisib;   Drug: Ibrutinib
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Bayer
    Recruiting

  • Condition:   Mucocutaneous Lymph Node Syndrome
    Interventions:   Drug: IVIG;   Drug: Infliximab
    Sponsors:   University of California, San Diego;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Kawasaki Disease
    Interventions:   Drug: IVIG;   Drug: Aspirin;   Drug: Prednisolone
    Sponsor:   Children's Hospital of Fudan University
    Not yet recruiting

  • Condition:   Kawasaki Disease
    Intervention:   Drug: Anakinra
    Sponsors:   University of California, San Diego;   Boston Children’s Hospital;   Cedars-Sinai Medical Center
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Pembrolizumab
    Sponsors:   Joshua Brody;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Kawasaki Disease
    Interventions:   Drug: Immunoglobulin G;   Drug: Acetylsalicylic acid
    Sponsor:   Green Cross Corporation
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Cisplatin;   Drug: Rituximab;   Drug: Thalidomide;   Drug: Prednisone
    Sponsor:   Institute of Hematology & Blood Diseases Hospital
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Not yet recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Acalabrutinib;   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Weill Medical College of Cornell University
    Not yet recruiting

  • Condition:   Mantle Cell Lymphoma
    Intervention:   Drug: Ixazomib
    Sponsors:   Ho Sup Lee;   Takeda
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: R-CHOP;   Drug: R-CHOP / R-HAD;   Drug: Rituximab;   Drug: Lenalidomide
    Sponsor:   The Lymphoma Academic Research Organisation
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Intervention:   Drug: DTRMWXHS-12
    Sponsor:   Zhejiang DTRM Biopharma
    Recruiting

  • Conditions:   Kawasaki Disease;   Coronary Artery Abnormalities
    Intervention:  
    Sponsor:   Children's Hospital of Fudan University
    Recruiting

  • Condition:   Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
    Interventions:   Drug: zanubrutinib;   Drug: bendamustine;   Drug: rituximab
    Sponsor:   BeiGene
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting

  • Condition:   Mantle-Cell Lymphoma
    Interventions:   Drug: Ixazomib;   Drug: Ibrutinib
    Sponsors:   PrECOG, LLC.;   Takeda
    Recruiting

  • Conditions:   Vasculitis, Systemic;   Kawasaki Disease
    Intervention:  
    Sponsor:   Medical University of Warsaw
    Not yet recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: bortezomib
    Sponsors:   Swiss Group for Clinical Cancer Research;   European Mantle Cell Lymphoma Network
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Ibrutinib
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Bendamustine;   Drug: Rituximab
    Sponsors:   PrECOG, LLC.;   Genentech, Inc.
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Acalabrutinib;   Drug: Cytarabine;   Procedure: Leukapheresis;   Procedure: Peripheral blood;   Procedure: Oral rinse;   Procedure: Bone marrow collection
    Sponsors:   Washington University School of Medicine;   Acerta Pharma BV
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Ixazomib;   Drug: Ixazomib Citrate;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Mantle Cell Lymphoma
    Interventions:   Drug: Ixazomib;   Biological: Rituximab
    Sponsors:   Emory University;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Intervention:   Drug: Low Dose Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Other: Best Practice;   Drug: Ibrutinib;   Other: Patient Derived Xenograft;   Other: Personalized Medicine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   B Cell Lymphoma
    Interventions:   Drug: Palbociclib;   Drug: Ibrutinib
    Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer
    Recruiting

  • Condition:   Relapsed/Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab
    Sponsors:   Lund University Hospital;   Celgene;   Janssen, LP;   Nordic Lymphoma Group
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Lymphoma
    Interventions:   Drug: BR-I (bendamustine, rituximab, ibrutinib);   Drug: VEN (Venetoclax)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Lymphoma, Mantle-Cell
    Intervention:   Drug: Venetoclax
    Sponsors:   Fondazione Italiana Linfomi ONLUS;   AbbVie
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma(DLBCL);   Mantle Cell Lymphoma (MCL);   Follicular Lymphoma (FL)
    Intervention:   Drug: AMG 562
    Sponsor:   Amgen
    Recruiting

  • Conditions:   Follicular Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: Ribavirin
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   B-cell Lymphoma
    Intervention:   Drug: AC0010MA
    Sponsor:   Hangzhou ACEA Pharmaceutical Research Co., Ltd.
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: Abexinostat;   Drug: Ibrutinib
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Janssen Scientific Affairs, LLC;   Xynomic Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Lymphoma, Mantle-cell;   CLL (Chronic Lymphocytic Leukemia);   Monoclonal B-Cell Lymphocytosis;   Healthy Volunteers;   Small Lymphocytic Lymphoma
    Intervention:  
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Northwell Health
    Recruiting

  • Conditions:   Kawasaki Disease;   Coronary Aneurysm
    Interventions:   Drug: Doxycycline;   Drug: Placebo
    Sponsor:   Hawaii Pacific Health
    Recruiting

  • Conditions:   CD20 Positive;   Mantle Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Ibrutinib;   Drug: Methotrexate;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: Loncastuximab Tesirine and Ibrutinib
    Sponsor:   ADC Therapeutics S.A.
    Recruiting

  • Conditions:   CD20 Positive;   Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Carcinoma, Renal Cell, Advanced;   Lymphoma, Mantle-Cell;   Gastrointestinal Stroma Tumors
    Interventions:   Drug: Temsirolimus;   Drug: Sunitinib;   Drug: Axitinib
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Blastoid Variant Mantle Cell Lymphoma;   CCND1 Protein Overexpression;   CD20 Positive;   CD5 Positive;   FCER2 Negative;   Pleomorphic Variant Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   t(11;14)(q13;q32)
    Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ALK Positive;   BCL6 Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Intervention:   Drug: Onalespib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CCND1 Positive;   CCND2 Positive;   CCND3 Positive;   CD20 Positive;   Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CCND1 Positive;   Mantle Cell Lymphoma;   t(11;14) Positive
    Interventions:   Drug: Bendamustine;   Biological: Obinutuzumab;   Drug: Venetoclax
    Sponsors:   Emory University;   Genentech, Inc.
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Non-hodgkin Lymphoma;   Non Hodgkin Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Obinutuzumab
    Sponsors:   University of Wisconsin, Madison;   Genentech, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CCND1 Positive;   CD20 Positive;   Mantle Cell Lymphoma
    Intervention:   Drug: Ibrutinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Mantle Cell Lymphoma
    Intervention:   Drug: Obinutuzumab
    Sponsors:   Polish Lymphoma Research Group;   Roche Pharma AG
    Recruiting

  • Conditions:   Phase I: Relapsed or Refractory B-cell Malignancies;   Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma;   Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
    Intervention:   Drug: Acalabrutinib
    Sponsor:   AstraZeneca
    Not yet recruiting

  • Condition:   Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
    Intervention:   Drug: MIK665
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Celgene
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: Parsaclisib
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Waldenström Macroglobulinemia
    Intervention:   Drug: Zanubrutinib
    Sponsor:   BeiGene
    Available

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma
    Intervention:   Drug: Loncastuximab Tesirine and Durvalumab
    Sponsor:   ADC Therapeutics S.A.
    Recruiting

  • Condition:   Lymphoma, Mantle Cell
    Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
    Sponsor:   Acerta Pharma BV
    Recruiting

  • Conditions:   HLRCC;   Sporadic Papillary Renal Cell Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Relapsed Non Hodgkin Lymphoma
    Intervention:   Drug: Venetoclax
    Sponsor:   Nordic Lymphoma Group
    Recruiting

  • Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, Mantle-Cell
    Intervention:   Drug: Ibrutinib
    Sponsor:   Janssen-Cilag Ltd.
    Recruiting

  • Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, Mantle-Cell
    Interventions:   Drug: Ibrutinib 420 mg;   Drug: Ibrutinib 560 mg
    Sponsor:   Johnson & Johnson Private Limited
    Recruiting

  • Conditions:   B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: Cirmtuzumab;   Drug: Ibrutinib;   Drug: Cirmtuzumab plus ibrutinib
    Sponsors:   University of California, San Diego;   California Institute for Regenerative Medicine (CIRM);   Oncternal Therapeutics, Inc
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Alvocidib;   Drug: Cytarabine;   Drug: Mitoxantrone
    Sponsor:   Tolero Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
    Interventions:   Drug: Vandetanib;   Drug: Metformin;   Drug: Vandetanib/Metformin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: LY3214996
    Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company
    Not yet recruiting

  • Conditions:   Adjuvant Chemotherapy;   Ovarian Neoplasms;   Ovarian Cancer
    Intervention:   Drug: PEG-rhG-CSF
    Sponsor:   Shandong University
    Recruiting

  • Condition:   HIV-1-infection
    Intervention:   Drug: Antiretroviral
    Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   Institut National de la Santé Et de la Recherche Médicale, France
    Not yet recruiting

  • Conditions:   Lymphoma, Large B-Cell, Diffuse;   Mantle Cell Lymphoma;   Peripheral T Cell Lymphoma;   Double-hit Lymphoma
    Intervention:   Drug: Chidamide
    Sponsor:   The First Affiliated Hospital with Nanjing Medical University
    Recruiting

  • Conditions:   Von Hippel-Lindau Disease;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Birt-Hogg-Dube Syndrome;   SDHB Gene Mutation
    Intervention:  
    Sponsors:   Ilene Sussman, PhD;   National Organization for Rare Disorders
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Relapsed/Refractory Advanced Solid Tumors;   Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma;   Relapsed/Refractory Myelodysplasia;   Relapsed/Refractory Myelofibrosis
    Intervention:   Drug: PRT543
    Sponsor:   Prelude Therapeutics
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group - NORD;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Diffuse Large B-cell Lymphoma (DLBCL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   Transformed Follicular Lymphoma (TFL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
    Interventions:   Biological: WZTL002-1 (1928T2z CAR-T cells);   Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
    Sponsors:   Malaghan Institute of Medical Research;   Wellington Zhaotai Therapies Limited
    Not yet recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma;   DLBCL;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: IGM-2323
    Sponsor:   IGM Biosciences, Inc.
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: ICP-022
    Sponsor:   Beijing InnoCare Pharma Tech Co., Ltd.
    Not yet recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    Intervention:   Biological: Inactivated Influenza Vaccine
    Sponsor:   Emory University
    Recruiting

  • Conditions:   B Cells-Tumors;   B Cell Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)
    Interventions:   Drug: Idelalisib 100 MG;   Drug: Placebo Oral Tablet
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Gilead Sciences
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Mantle-cell Lymphoma;   Primary Mediastinal B-cell Lymphoma
    Interventions:   Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule;   Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
    Sponsors:   Juno Therapeutics, Inc.;   Celgene
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoplasmacytoid Lymphoma;   Mantle-Cell Lymphoma;   Waldenstrom Macroglobulinemia;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: SNS-062
    Sponsor:   Sunesis Pharmaceuticals
    Recruiting

  • Conditions:   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
    Interventions:   Drug: Selinexor;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
    Sponsors:   Jennifer Woyach;   National Cancer Institute (NCI);   Karyopharm Therapeutics Inc
    Recruiting

  • Conditions:   Central Nervous System Lymphoma;   Gastric Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Splenic Mantle Cell Lymphoma
    Interventions:   Drug: Akt/ERK Inhibitor ONC201;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL);   Marginal Zone Lymphoma (MZL);   Small Lymphocytic Lymphoma (SLL);   Chronic Lymphocytic Leukemia (CLL);   Diffuse Large B-cell Lymphoma (DLBCL);   Acute Myeloid Leukemia (AML)
    Intervention:   Drug: Voruciclib
    Sponsor:   MEI Pharma, Inc.
    Recruiting

  • Conditions:   Diffuse Large B Lymphoma (DLBCL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL);   Marginal Zone Lymphoma (MZL);   T-cell Lymphoma (T-NHL);   Hodgkin's Lymphoma (HL);   Burkitt Lymphoma (BL))
    Intervention:   Other: Real-life epidemiological platform of lymphoma in France
    Sponsors:   Hospices Civils de Lyon;   The Lymphoma Academic Research Organisation
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   B-cell Lymphoma;   Small Lymphocytic Lymphoma
    Intervention:   Drug: LOXO-305
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   ACL Repair;   Posterior Cruciate Ligament (PCL) Repair;   Medial Collateral Ligament (MCL);   Lateral Collateral Ligament (LCL);   Posterior Oblique Ligament (POL);   Patellar Realignment and Tendon Repairs;   Vastus Medialis Obliquus Advancement;   Iliotibial Band Tenodesis;   Extra-capsular Repairs;   Knee Repair
    Intervention:  
    Sponsor:   Smith & Nephew, Inc.
    Recruiting

  • Conditions:   Lymphoma, T-Cell, Cutaneous;   Lymphoma, T-Cell, Peripheral;   Chronic Lymphocytic Leukemia;   Lymphoproliferative Disorders;   Waldenstrom Macroglobulinemia;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: Pacritinib
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   Follicular Lymphoma (FL);   Marginal Zone B Cell Lymphoma;   Diffuse Large B-cell Lymphoma (DLBCL);   High Grade Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma (MCL)
    Interventions:   Drug: ME-401;   Drug: Rituximab;   Drug: Zanubrutinib
    Sponsor:   MEI Pharma, Inc.
    Recruiting

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blastoid Variant Mantle Cell Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Intervention:   Drug: CD19.CAR-T cells
    Sponsors:   Xinqiao Hospital of Chongqing;   Xuzhou Medical University;   Hrain Biotechnology Co., Ltd.;   Shanghai Changzheng Hospital
    Recruiting

  • Conditions:   Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Intervention:   Biological: anti-CD19/20-CAR vector-transduced T cells
    Sponsor:   Chinese PLA General Hospital
    Recruiting

  • Conditions:   Rupture of Anterior Cruciate Ligament;   Osteoarthritis
    Intervention:   Procedure: Ligament of the knee reconstruction
    Sponsor:   Fonds de Dotation pour la Recherche Clinique en Orthopédie et Pathologie du Sport
    Recruiting

  • Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
    Not yet recruiting

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Pevonedistat;   Other: Pharmacokinetic Study;   Other: Pharmacological Study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Extranodal Marginal Zone Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Stage III Non-Hodgkin Lymphoma;   Stage IV Non-Hodgkin Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
    Intervention:   Drug: Selinexor
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Drug: Fludarabine Phosphate
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Mediastinal Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Blinatumomab;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma, B-Cell;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma;   Richter's Transformation;   Follicular Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: ARQ 531
    Sponsor:   ArQule
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   Richter Transformation Lymphoma
    Intervention:   Drug: VLS-101
    Sponsor:   VelosBio Inc.
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Peripheral T-cell Lymphoma (PTCL);   Cutaneous T-cell Lymphoma (CTCL);   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   Follicular Lymphoma;   Marginal Zone Lymphoma;   Hodgkin Lymphoma;   Waldenstrom Macroglobulinemia
    Intervention:   Drug: L-Bcl-2 antisense oligonucleotide
    Sponsor:   Bio-Path Holdings, Inc.
    Not yet recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Indolent B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Primary Cutaneous Follicle Centre Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Mantle Cell Lymphoma;   Plasma Cell Neoplasm;   B Cell Lymphoma
    Intervention:   Drug: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
    Sponsors:   PersonGen BioTherapeutics (Suzhou) Co., Ltd.;   Anhui Provincial Hospital
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma;   High-grade B-cell Lymphoma;   Primary Mediastinal Large B-cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Biological: GEN3013 (DuoBody®-CD3xCD20)
    Sponsor:   Genmab
    Recruiting

  • Conditions:   B-cell Lymphoma;   Non Hodgkin Lymphoma;   Multiple Myeloma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma;   Indolent Lymphoma;   B Cells--Tumors
    Intervention:   Drug: STRO-001
    Sponsor:   Sutro Biopharma, Inc.
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignancy;   Non-hodgkin Lymphoma;   Multiple Myeloma;   Breast Cancer;   Ovarian Cancer;   Soft Tissue Sarcoma;   Squamous Cell Carcinoma;   Head and Neck Cancer;   DLBCL;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Leiomyosarcoma;   Pancreatic Cancer;   Sarcoma;   CLL
    Intervention:   Drug: CYT-0851
    Sponsor:   Cyteir Therapeutics, Inc.
    Not yet recruiting

  • Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
    Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   B-Cell Non-Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Anti-OX40 Antibody BMS 986178;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: TLR9 Agonist SD-101
    Sponsors:   Ronald Levy;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   JAK2 Gene Mutation;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   RAS Family Gene Mutation;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hematologic Malignancy;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome;   TP53 Gene Mutation
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Irradiated Allogeneic Cells
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Breast Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Ovarian Cancer;   Cholangiocarcinoma;   Bladder Urothelial Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Cancer;   Esophageal Cancer;   Hepatic Cancer;   Head and Neck Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Other Solid Tumors;   Diffuse Large B-cell Lymphoma (DLBCL);   Mantle Cell Lymphoma;   Indolent B-cell Lymphomas;   Non-Hodgkin Lymphoma
    Interventions:   Drug: CDX-1140;   Drug: CDX-301
    Sponsor:   Celldex Therapeutics
    Recruiting

  • Conditions:   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   Mantle-Cell Lymphoma;   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: CLR 131 single dose;   Drug: CLR 131 multiple dose
    Sponsor:   Cellectar Biosciences, Inc.
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
    Interventions:   Drug: Ibrutinib;   Radiation: Radiation Therapy;   Drug: TLR9 Agonist SD-101
    Sponsors:   Robert Lowsky;   Janssen, LP;   National Institutes of Health (NIH)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
    Interventions:   Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide
    Sponsor:   University of Arizona
    Recruiting

  • Conditions:   Bankart Lesion;   Acetabular Labrum Tear;   SLAP Lesion;   Acromioclavicular Sprain;   Capsular Shift/Capsulolabral Reconstruction;   Deltoid Repair;   Rotator Cuff Repair;   Bicep Tendinitis;   Extra-capsular Repair;   Medial Collateral Ligament;   Lateal Collateral Ligament;   Posterior Oblique Ligament;   IBT;   Vastus Medialis;   Obliquus Advancement;   Joint Capsule Closure
    Intervention:   Device: The Q-Fix™ All-Suture Anchor
    Sponsor:   Smith & Nephew, Inc.
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Procedure: Cryosurgery;   Biological: Dendritic Cell Therapy;   Biological: Pembrolizumab;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Lymphoma
    Interventions:   Drug: Parsaclisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Hematological Malignancies
    Intervention:   Drug: CBL0137
    Sponsor:   Incuron
    Recruiting

  • Conditions:   Relapsed Hematologic Malignancy;   Refractory Hematologic Malignancy
    Intervention:   Drug: CA-4948
    Sponsor:   Curis, Inc.
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: HMPL-689
    Sponsor:   Hutchison Medipharma Limited
    Not yet recruiting

  • Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
    Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Gastrointestinal Stromal Tumors;   Advanced Systemic Mastocytosis;   Advanced Cancers
    Intervention:   Drug: DCC-2618
    Sponsor:   Deciphera Pharmaceuticals LLC
    Recruiting

  • Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Device: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AML;   MDS
    Interventions:   Drug: CYC065;   Drug: Venetoclax
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Relapsed or Refractory Chronic Lymphocytic Leukemia
    Interventions:   Drug: CYC065;   Drug: Venetoclax
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Mature B-Cell Neoplasm
    Intervention:   Diagnostic Test: Liquid Biopsy
    Sponsor:   Oncology Institute of Southern Switzerland
    Recruiting

  • Conditions:   B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Intervention:   Biological: XmAb13676
    Sponsors:   Xencor, Inc.;   Chiltern International Inc.
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Itacitinib;   Drug: Calcineurin inhibitor
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
    Interventions:   Drug: Pralatrexate;   Drug: Romidepsin
    Sponsor:   Jennifer Amengual
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Radiation: Radiation Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting